Akers Biosciences to Present at 8th Annual LD Micro Investor Conference

Nov. 30, 2015 7:00 am |  More About Akers Biosciences


THOROFARE, N.J., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ:AKER) (AIM:AKR.L), ("Akers Bio" or the "Company"), a developer of cutting edge technologies that deliver rapid health information, is participating in the 8th Annual LD Micro Investor Conference taking place in Los Angeles, CA from December 1-3, 2015.

Executive Chairman, Raymond F. Akers Jr., Ph.D, will present to institutional and private investors attending the conference on December 2, 2015.

About LD Micro

LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space.

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

CONTACT: For more information:
         
         Akers Biosciences, Inc.
         Raymond F. Akers, Jr. PhD
         Executive Chairman of the Board
         Tel. +1 856 848 8698
         
         Taglich Brothers, Inc. (Investor Relations)
         Chris Schreiber
         Tel. +1 917 445 6207
         cs@taglichbrothers.com
         
         finnCap (UK Nominated Adviser and Broker)
         Adrian Hargrave / Scott Mathieson (Corporate Finance)
         Steve Norcross (Broking)
         Tel. +44 (0)20 7220 0500
         
         Vigo Communications (Public Relations)
         Ben Simons / Fiona Henson
         Tel. +44 (0)20 7016 9570
         akers@vigocomms.com

Akers Bio logo

<

GlobeNewswire
November 30, 2015 - 7:00 AM EST


comments powered by Disqus

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market